Skip to main content

Table 3 Patient distribution in treatment cohorts, Prev-AP FAS and New-AP CMD-set

From: Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics - results from a German observational study

Cohorts Prev-AP, FAS (N = 642)

 

N (%)

Prev-Olz

previous olanzapine monotherapy

62 (9.7%)

Prev-Risp

previous risperidone monotherapy

67 (10.4%)

Prev-Quet

previous quetiapine monotherapy

49 (7.6%)

Prev-Atyp

previous other atypical antipsychotic monotherapy (amisulpride, aripiprazoleclozapine, ziprasidone, paliperidone)

103 (16.0%)

Prev-Typ

previous typical antipsychotics

90 (14.0%)

Prev-Comb

any previous combination therapy

109 (17.0%)

Prev-None

not treated with antipsychotics within6 months prior to study entry

162 (25.2%)

Cohorts New-AP, CMD-set (N = 476)

 

N (%)

New-Olz

new olanzapine monotherapy

206 (43.3%)

New-Risp

new risperidone monotherapy

69 (14.5%)

New-Quet

new quetiapine monotherapy

33 (6.9%)

New-Atyp

new other atypical antipsychotic monotherapy (amisulpride, aripiprazoleclozapine, ziprasidone, paliperidone)

72 (15.1%)

New-Typ

new typical antipsychotic

16 (3.4%)

New-Comb

new combination therapy (any combination)

80 (16.8%)

  1. Abbreviations: CMD = complete metabolic data; FAS = full analysis set; New-AP = new antipsychotic treatment cohort; Prev-AP = previous antipsychotic treatment cohort;